Natural compound screening platform for 5-alpha reductase inhibitors

Overview

This research program focuses on discovering natural compounds that inhibit 5-alpha reductase, an enzyme implicated in prostate inflammation and related conditions. The approach leverages a broad library of phenolic compounds and phytosterols sourced from medicinal plants, exploiting the well-documented relationship between antioxidant properties and enzyme inhibition activity. By combining computational screening with laboratory validation, the program aims to identify novel plant-derived candidates that could serve as active ingredients for nutraceutical, cosmetic, or pharmaceutical applications targeting androgen-related disorders.

Technical specifications

Research workflow:

• Selection of medicinal plants with demonstrated anti-inflammatory properties
• Preparation and characterization of herbal extracts with full phytochemical profiling
• In silico screening using network pharmacology and molecular docking to predict which extracts and isolated phytochemicals target 5-alpha reductase
• In vitro validation using the PC3 human prostate cell line, with cells pre-treated or co-treated with extracts and isolated compounds
• Exposure to LPS (lipopolysaccharide from E. coli) to simulate inflammation and oxidative stress characteristic of prostatitis
• Measurement of cell viability and gene expression of 5-alpha reductase, COX-2, iNOS, NFkB, and inflammatory cytokines

Scientific rationale:

• Phenolics and phytosterols exhibit dual antioxidant and enzyme inhibition properties
• Classical pharmaceutical biology assays evaluate intrinsic antioxidant and enzyme inhibition activity of herbal extracts in cell-free models
• Analytical and computational methods identify the specific phytochemicals responsible for biological effects

Technology readiness level

This research is currently at the discovery and early validation stage. The methodology combines established in silico modeling techniques with standard in vitro cell-based assays. Future validation will progress through systematic screening of selected medicinal plants, computational prediction of active compounds, and biological confirmation in prostate cell models under inflammatory conditions. The program is positioned to generate lead candidates for further development toward nutraceutical or pharmaceutical applications targeting 5-alpha reductase-related conditions.